Relmada Therapeutics recently reported past 12‑month interim Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results